Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study

Ostojić, Alen and Sertić, Dubravka and Rončević, Pavle and Perić, Zinaida and Granić, Paula and Matić, Nikolina and Bašić-Kinda, Sandra and Serventi-Seiwerth, Ranka and Radman, Ivo and Zadro, Renata and Nemet, Damir (2016) Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study. Clinical Lymphoma Myeloma and Leukemia, 16 (8). pp. 472-476. ISSN 2152-2650

[img] PDF - Accepted Version
Download (994kB)


INTRODUCTION: For over a decade, imatinib has been the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Doubts on the bioequivalence and bioavailability of emerging generic compounds have been expressed. Adequate imatinib plasma concentration ([IPC] ≥1000 μmol/L) is associated with a better chance of optimal treatment response in patients with CML. In this study, we compared the achieved IPCs between the branded compound and its 2 generic forms. ----- PATIENTS AND METHODS: IPCs were compared in 24 consecutive patients with CML in the first chronic phase who changed from branded to generic imatinib. The median age was 49 years (range, 22-76 years). Fifteen of them were male. Six patients were switched to Neopax, 13 to Imakrebin, and 5 patients received both generics consecutively. All compounds were used in an equivalent dose of 400 mg orally once daily for at least 1 month before plasma concentrations were measured. High-performance liquid chromatography was used to determine imatinib plasma concentration from a specimen collected 21 to 24 hours after the last dose. ----- RESULTS: The median IPC achieved with branded imatinib was 1454 μmol/L (range, 485-2707 μmol/L) with 18 patients (75%) having IPC ≥ 1000 μmol/L. For Neopax and Imakrebin, median IPCs were 1717 μmol/L (range, 1249-3630 μmol/L) and 1458 μmol/L (range, 707-880 μmol/L), respectively, with 11 of 11 (100%) and 16 of 18 (89%) patients having IPC ≥ 1000 μmol/L. No significant difference in measured IPCs between all 3 compounds was found (P > .257). ----- CONCLUSION: When taken at equivalent doses, imatinib generics are bioequivalent and comparable in clinical efficacy and have the potential for substantial savings in the treatment cost for CML.

Item Type: Article
MeSH: Adult ; Aged ; Antineoplastic Agents/pharmacokinetics ; Drug Costs ; Drug Monitoring ; Drugs, Generic ; Female ; Humans ; Imatinib Mesylate/pharmacokinetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Male ; Medication Adherence ; Middle Aged ; Protein Kinase Inhibitors/pharmacokinetics ; Therapeutic Equivalency ; Young Adult
Departments: Katedra za internu medicinu
Katedra za medicinsku kemiju, biokemiju i kliničku kemiju
Depositing User: Martina Žužak
Status: Published
Sertić, DubravkaUNSPECIFIED
Rončević, PavleUNSPECIFIED
Matić, NikolinaUNSPECIFIED
Bašić-Kinda, SandraUNSPECIFIED
Serventi-Seiwerth, RankaUNSPECIFIED
Date: August 2016
Date Deposited: 11 Dec 2017 11:35
Last Modified: 17 Aug 2020 06:47
Related URLs:

Actions (login required)

View Item View Item


Downloads per month over past year